What is Geneseeq?
Geneseeq Technology Inc. is a leading Precision Oncology Company specializing in advanced Next-Generation Sequencing (NGS)-based solutions. Their expertise spans cancer diagnosis, prognosis, treatment guidance, and drug development, providing oncologists, researchers, and patients with actionable genomic insights across solid tumors and hematologic malignancies. The company's comprehensive suite of services includes central lab testing, local testing solutions, and customized research services, all designed to accelerate precision cancer care. Geneseeq actively collaborates with biopharma and research partners, leveraging high-quality genomic data to support translational research and advance the field of oncology.
How much funding has Geneseeq raised?
Geneseeq has raised a total of $127.9M across 3 funding rounds:
Series A
$4.8M
Series B
$9.1M
Series D
$114M
Series A (2014): $4.8M with participation from Beijing Beilu Pharmaceutical
Series B (2016): $9.1M led by Beijing Beilu Pharmaceutical, Eastern Investment, and Beijing D.Z Capital
Series D (2019): $114M supported by China Reform Holdings Corporation, Lilly Asia Ventures, and SoftBank China Venture Capital
Key Investors in Geneseeq
Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co. Ltd is a Chinese pharmaceutical company operating in the drug manufacturing sector, likely providing strategic backing for companies in related health and life sciences industries.
Lilly Asia Ventures
Lilly Asia Ventures is a leading biomedical venture capital firm focused on investing in breakthrough products that treat diseases and improve human health, indicating a strong interest in innovative healthcare and life sciences companies.
SoftBank China Venture Capital
SoftBank China Venture Capital is a venture capital firm that invests in technology and innovation, suggesting a focus on companies with high growth potential and disruptive technologies within the tech and biotech sectors.
What's next for Geneseeq?
With a significant enterprise-level funding history and a recent strategic investment, Geneseeq is well-positioned for accelerated growth and market leadership in precision oncology. The company's focus on advanced NGS-based solutions for cancer diagnosis and treatment guidance indicates a strategic direction towards expanding its service portfolio and deepening its collaborations with biopharmaceutical and research entities. Future endeavors will likely involve further development of its genomic data platforms, enhancement of its testing capabilities, and broader market penetration to support the global advancement of personalized cancer care.
See full Geneseeq company page
